

COVID-19 VACCINE SCREENING & CONSENT

Clinic Location/Facility Name:	Today's Date (yyyy/min/dd	Today's Date (yyyy/mm/dd):							
CLIENT INFORMATION									
First Name:									
Date of Year Month Day Age Birth:	☐ Male ☐ Female ☐] Other							
Health Card #	Email:								
Address:	Postal Code: Prima	ary Phone:							
SC	REENING QUESTIONS								
Have you been diagnosed with myocarditis or mRNA COVID-19 vaccine?		f an Yes No							
Have you ever had myocarditis or pericard	☐ Yes ☐No								
Do you have (or have you recently had) ar	☐ Yes ☐No								
Have you been sick in the past few days? Do fever today?	ve a Yes No								
Have you had a serious allergic reaction withi	re?								
Do you have allergies to polyethylene glyco or polysorbate?	zer only) Yes No								
Have you had a serious allergic reaction to a IV, IM), needing medical care?	tion (e.g., Yes No								
Do you have a weakened immune system or your immune system (e.g., high dose steroids If yes, are you receiving stem cell therapy, CA inhibitors, monoclonal antibodies, or other targets.	□ Yes □No								
Do you have a bleeding disorder or are taking	☐ Yes ☐ No								
Have you ever felt faint or fainted after receivi	☐ Yes ☐ No								
Do you have any questions?If yes, please									
Have you had a previous dose of COVID-19 \ Dose 1 date (yyyy/mm/dd) Does 2 date (yyyy/mm/dd) Does 3 date (yyyy/mm/dd)	Product Name:Product Name:	☐ Yes ☐No							

CONSENT & COLLECTION OF INFORMATION

For individuals receiving a different mRNA vaccine for their second dose following Pfizer BioNTech or Moderna:

The same mRNA COVID-19 vaccine product should be offered for the second dose in a vaccine series started with an mRNA COVID-19 vaccine if available in the clinic. If the mRNA COVID-19 vaccine used for the first dose

is not readily available in the clinic or is unknown, another mRNA COVID-19 interchangeable and should be offered to complete the vaccine series.	vaccine product can be considered				
☐ I acknowledge that I have read and understand this information					
For individuals choosing to receive an mRNA vaccine following AstraZeneca COVID-19 vaccine: Individuals who received AstraZeneca for their first dose may choose to receive either AstraZeneca for their second dose or an mRNA vaccine. A dosing interval between eight and 12 weeks is safe and demonstrates a beneficial immune response. There is evidence that a longer interval between two doses of the AstraZeneca vaccine (such as a 12-week interval) provides higher protection					
I acknowledge that I have read and understand this information					
I have read The Regional Municipality of York's COVID-19 Vaccine Information Sheet or it has been read to me. I understand the benefits and possible side effects of the vaccine and that certain persons listed on the Information Sheet should not get the COVID-19 vaccine. I have had an opportunity to have my questions answered from a representative of the clinic location/facility.					
 I consent to receiving the COVID-19 vaccine, including all recommended doses in the series I understand that I may withdraw this consent at any time. FOR CLIENTS LIVING IN CONGREGATE CARE SETTINGS (example: long-term care homes and retirement homes) I understand that if I am withdrawing consent as a substitute decision maker of an individual, then I must contact the congregate care setting that the individual resides in. 					
Acknowledgement of Collection, Use and Disclosure of Personal	Health Information				
The personal health information on this form is being collected for the purpose of providing care to you and creating an immunization record for you, and because it is necessary for the administration of Ontario's COVID-19 vaccination program. This information will be used and disclosed for these purposes, as well as other purposes authorized and required by law. For example, it will be disclosed to the Chief Medical Officer of Health and Ontario public health units where the disclosure is necessary for a purpose of the <i>Health Protection and Promotion Act</i> . It may also be disclosed, as part of your provincial electronic health record, to health care providers who are providing care to you. The information will be stored in a health record system under the custody and control of the Ministry of Health.					
$\ \ \square$ I acknowledge that I have read and understand the above statement.					
You may be contacted for purposes related to the COVID-19 vaccine (for example, to remind you of follow up appointments and to provide you with proof of vaccination).					
$\ \ \square$ I consent to receiving follow-up communications by email or by text	/SMS				
Consent to Being Contacted About Research Studies					
You have the option of consenting to be contacted by researchers about part research studies. If you consent to be contacted, your personal health inform studies may be relevant to you, and your name and contact information will be Consenting to be contacted about research studies does not mean you have research itself. Participating is voluntary. You may refuse to consent to be co without impacting your eligibility to receive the COVID-19 vaccine. If you constudies, and then change your mind, you may withdraw your consent at any the Health at Vaccine@ontario.ca .	ation will be used to determine which be disclosed to researchers. consented to participate in the intacted about research studies sent to be contacted about research.				
☐ I consent to be contacted about COVID-19 vaccine related research s	tudies:				
 □ by email □ by text/SMS □ by phone □ by mail □ I do not consent to be contacted about COVID-19 related research st 	rudies				
Client Signature:	Date signed:				
PARENT/LEGAL CHARDIAN/SUBSTITUTE DECISION MAK	ER (SDM) CONSENT				
PARENT/LEGAL GUARDIAN/SUBSTITUTE DECISION MAK Required for children under 12 years of age and others who are unal	ble to provide their own consent				
If applicable: Parent/Legal Guardian/SDM Full Name: If applicable: Parent/Legal Guardian/SDM Signature:	Date Signed:				

not entered into COVAX Client Full Name:			(Client DOB:	
COVID-19 Product Name:			I	Lot #	
Diluent Lot #	□N/A	Dose	volume	e:	
Route and Anatomical Site: IM	- Right Deltoid		l – Left	t Deltoid	
Date given (yyyy/mm/dd):		given:	ven:		
Dose Number:				eceiving current dose? No	
Reason for Immunization:		L			
☐Child/Youth 5+	☐ Age priority population – Age eligible population		n –	Other reason:	
Reason for Paper Documentation	n:				
☐ No consent for COVax entry	COVax unavailable			Other:	
Immunizer Full Name and Designation:					
Immunizer Signature:					
Complete below if immur	nization not	aive	1		
Reason immunization not given: Immunization is contraindicated HCP decision to temporarily defe Medically ineligible Client withdrew consent HCP recommends immunization Below minimum monograph age	er immunization n but no client co				
For ACI/office use only to document post- entry into COVax as appropriate	-clinic data Date/time	e entered	(office u	use only) Printed Name (office use only)	